Vanguard Capital Management Acquires 7.37% Stake in Regeneron Pharmaceuticals Inc

On April 30, 2026, Vanguard Capital Management LLC filed a Schedule 13G with the SEC, disclosing a significant new ownership stake in Regeneron Pharmaceuticals Inc (REGN). As of the event date of March 31, 2026, Vanguard reported beneficial ownership of 7,660,810 shares of Common Stock, representing 7.37% of the company's total shares outstanding. This filing marks an increase from a previous ownership level of 0.0%, establishing Vanguard as a major institutional shareholder. The filing indicates that Vanguard holds sole dispositive power over all 7,660,810 shares, while maintaining sole voting power over 1,005,897 shares. The securities were acquired in the ordinary course of business and are not held for the purpose of influencing or changing the control of the issuer. The reported holdings include shares managed by various Vanguard affiliates, including Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. No other single person's interest in these securities exceeds 5% of the total class.